Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IMPROVED EXCIPIENT ANALYSIS AND CONTROL

This article was originally published in The Gold Sheet

Executive Summary

...is being targeted as a key element in advancing quality by design and quality systems in pharmaceutical manufacturing. Excipient suppliers, users, pharmacopeias and regulatory agencies are searching together for ways to open communication pathways so that better analytical choices can be made and GMP needs clarified and met. A recent Product Quality Research Institute workshop on excipient testing and control strategies assessed the current communication challenges and the efforts under way to address them. [A report on Wyeth’s work on excipient QbD under FDA’s CMC pilot program is included.]

Latest Headlines
See All
UsernamePublicRestriction

Register

PS000090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel